Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia

阿扎胞苷 癸他滨 威尼斯人 髓系白血病 医学 耐火材料(行星科学) 白血病 癌症研究 肿瘤科 内科学 化学 生物 DNA甲基化 生物化学 基因表达 慢性淋巴细胞白血病 天体生物学 基因
作者
Yue Che,Wen Tan,Ying Liu,Haitao Liu,Lanlan Li,Fangmei Qin
出处
期刊:Tropical Journal of Pharmaceutical Research [Pharmacotherapy Group, University of Benin, Benin City]
卷期号:23 (1): 209-214
标识
DOI:10.4314/tjpr.v23i1.26
摘要

Purpose: To investigate the clinical effects of venetoclax combined with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia. Methods: 208 eligible first-line participants, who were diagnosed and treated for relapsed/refractory acute myeloid leukemia between January 2022 and December 2022, were recruited from the Department of Hematology of Loudi Central Hospital, China. The patients were randomly divided into study and control groups at the point of recruitment. Patients in the control group received venetoclax combined with decitabine, while those in the study group received venetoclax in combination with azacitidine. Clinical data for the two groups were recorded. The primary endpoints of this study included efficacy, routine blood indices, and adverse reactions. Results: There was no statistically significant difference in baseline characteristics between the two groups (p > 0.05), indicating comparability. The total effectiveness of the treatment (i.e., efficacy) in the study group was higher than in the control group (p < 0.05), while the control group had a higher risk of platelet, red blood cell, and neutrophil absolute count reduction than the study group (p < 0.05). The platelet count and hemoglobin level were lower in the control group after treatment compared to the study group (p < 0.05). Conclusion: The combination of venetoclax with azacitidine improves the efficacy and blood routine indices of patients with relapsed/ refractory acute myeloid leukemia, while reducing adverse reactions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哎呀妈呀完成签到,获得积分10
刚刚
干净海秋发布了新的文献求助10
1秒前
1秒前
3秒前
3秒前
4秒前
Evooolet完成签到,获得积分10
4秒前
ding应助凡是过往皆为序章采纳,获得10
6秒前
干净海秋完成签到,获得积分10
6秒前
小蘑菇应助zd采纳,获得10
6秒前
Ava应助别偷我增肌粉采纳,获得30
6秒前
abc完成签到,获得积分10
7秒前
一点通发布了新的文献求助10
8秒前
11秒前
淡淡的豁应助棒棒采纳,获得150
13秒前
小秋完成签到,获得积分10
13秒前
华仔应助木木林采纳,获得10
13秒前
QIZH发布了新的文献求助10
13秒前
FashionBoy应助py999采纳,获得10
14秒前
小马甲应助圆蓬蓬采纳,获得10
15秒前
15秒前
Orange应助陈念采纳,获得10
16秒前
16秒前
热心又蓝完成签到,获得积分10
17秒前
111发布了新的文献求助10
17秒前
曾经晓亦发布了新的文献求助20
17秒前
量子星尘发布了新的文献求助10
17秒前
FashionBoy应助一点通采纳,获得10
17秒前
害怕的冬云完成签到,获得积分10
18秒前
丘比特应助nni采纳,获得20
20秒前
陈一完成签到 ,获得积分10
20秒前
现代完成签到,获得积分10
21秒前
尹天奇发布了新的文献求助10
21秒前
21秒前
SYLH应助QIZH采纳,获得10
22秒前
结实的泥猴桃完成签到 ,获得积分10
23秒前
tex关闭了tex文献求助
24秒前
bkagyin应助薯条派采纳,获得10
24秒前
24秒前
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975755
求助须知:如何正确求助?哪些是违规求助? 3520108
关于积分的说明 11200829
捐赠科研通 3256492
什么是DOI,文献DOI怎么找? 1798298
邀请新用户注册赠送积分活动 877509
科研通“疑难数据库(出版商)”最低求助积分说明 806403